Enanta Pharmaceuticals, Inc.
NASDAQ:ENTABiotechnology
-$0.09 today
- Market cap
- $239.70M
- Beta
- 0.99
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$2.90
Volume 0.81M
Average 0.17M
ENTA Total Liabilities
Everything the company owes to creditors and other parties.
Enanta Pharmaceuticals, Inc.NASDAQ: ENTA
Total Liabilities · Q2 FY2026 · quarter ended Mar 2026
Total liabilities falls 13.7% from a year ago
Total liabilities stood at $198.12M at the end of Q2 FY2026, down 13.7% from a year earlier and down 2.4% from the prior quarter. Over 3 fiscal years it compounded at +53.9% a year.
Context
- Total liabilities amounted to 63.0% of total assets at the end of Q2 FY2026, down 8.1 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -13.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 216.02M USD
- Year-over-year change
- -12.8%
- 4-year CAGR
- +51.1%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 216.02M | -12.8% |
| FY2024 | 2024-09-30 | 247.84M | +0.9% |
| FY2023 | 2023-09-30 | 245.54M | +314.4% |
| FY2022 | 2022-09-30 | 59.26M | +43.0% |
| FY2021 | 2021-09-30 | 41.43M | — |
Total Liabilities vs competitors
How ENTA compares with its peers on the latest reported figures
- ENTA's Mar 2026 total liabilities of $198.12M is the 3rd highest of the 11 companies compared; the peer median is $41.28M.
- Its year-over-year change of -13.7% is the 8th highest of 11, against a peer median of +0.6%.
- Total liabilities amounts to 63.0% of total assets for ENTA, versus a peer median of 21.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $8.29B | +93713.8% | +2.6% | 3.9% | |
| Mar 2026 | $298.58M | -6.8% | -8.8% | 134.4% | |
| Mar 2026 | $198.12M | -13.7% | +53.9% | 63.0% | |
| Mar 2026 | $59.46M | +56.1% | +42.6% | 49.7% | |
| Mar 2026 | $46.98M | -16.8% | -10.0% | 31.5% | |
| Mar 2026 | $45.66M | -43.3% | -17.6% | 20.8% | |
| Mar 2026 | $36.9M | -48.7% | +38.5% | 15.7% | |
| Mar 2026 | $33.37M | +15.5% | +15.0% | 12.5% | |
| Mar 2026 | $33.36M | +0.3% | -0.9% | 18.8% | |
| Mar 2026 | $33.03M | +0.8% | -9.0% | 51.4% | |
| Mar 2026 | $28.88M | +17.6% | -12.7% | 21.4% | |
| Peer median (excluding ENTA) | $41.28M | +0.6% | -4.9% | 21.1% | |
Competitors are the stored peer set for ENTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 57.21M | 43.99M | 85.39M | 37.23M | 32.3M |
| Short-term Investments | 186.8M | 205.24M | 284.52M | 210.95M | 156.57M |
| Net Receivables | 60.83M | 49.04M | 39.62M | 38.65M | 6.88M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 13.26M | 608K | 8.59M |
| Total Current Assets | 319.02M | 311.71M | 422.79M | 299.85M | 204.34M |
| Property, Plant & Equipment (Net) | 10.65M | 29.75M | 34.71M | 73.35M | 72.94M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 109.02M | 33.25M | 3.97M | 3.36M | 3.36M |
| Tax Assets | 2.07M | 5.18M | 0 | 0 | 0 |
| Other Non-current Assets | 92K | 696K | 803K | 94K | 92K |
| Total Non-current Assets | 121.84M | 68.88M | 39.48M | 76.8M | 76.4M |
| Total Assets | 440.86M | 380.59M | 462.28M | 376.65M | 280.73M |
| Account Payables | 9.54M | 6M | 4.1M | 8M | 1.95M |
| Short-term Debt | 0 | 0 | 0 | 34.46M | 30.71M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 16.34M | 14.5M | 35.08M | 0 | 0 |
| Total Current Liabilities | 36.17M | 29.83M | 62.79M | 57.54M | 48.56M |
| Long-term Debt | 1.51M | 1.42M | 0 | 136.13M | 112.44M |
| Deferred Tax Liabilities | 2.07M | 5.18M | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 558K | 454K | 161.52M | 231K | 260K |
| Total Non-current Liabilities | 5.26M | 29.43M | 182.75M | 190.3M | 167.46M |
| Total Liabilities | 41.43M | 59.26M | 245.54M | 247.84M | 216.02M |
| Common Stock | 202K | 208K | 211K | 212K | 214K |
| Retained Earnings | 48.58M | (73.18M) | (207M) | (323.04M) | (404.93M) |
| Accumulated OCI | (382K) | (3.72M) | (1.17M) | 302K | (339K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 399.43M | 321.33M | 216.74M | 128.81M | 64.72M |
| Total Debt | 6.84M | 26.69M | 26.51M | 226.06M | 201.06M |
| Net Debt | (50.37M) | (17.31M) | (58.88M) | 188.83M | 168.76M |
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
Intrinsic Alpha fair value
Locked
Current Price
$8.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.